Join us for an insightful discussion with Drs. Natalia Neparidze and Saad Z. Usmani as we explore treatment strategies for relapsed multiple myeloma following BCMA-targeted therapy failure. With CAR T-cell therapy and bispecific antibodies revolutionizing myeloma treatment, clinicians are now faced with new challenges as patients relapse after BCMA-directed therapies.
Through the case of a 62-year-old woman who relapsed one year post-BCMA CAR T-cell therapy, we will discuss mechanisms of resistance, treatment sequencing, and the role of novel agents like selinexor-pomalidomide-dexamethasone. This episode will provide hematologists with practical strategies to navigate post-BCMA treatment failure and optimize patient outcomes.
Learning Objectives
- Understand mechanisms of resistance and progression following BCMA-targeted therapy.
- Explore non-BCMA treatment options, including alternative targets and novel agents.
- Recognize key factors influencing treatment selection and patient management.
What is HemeTalks: Conversations in Hematology Education?
HemeTalks: Conversations in Hematology Education is an American Society of Hematology (ASH) podcast for community hematologists, advanced practice providers, and trainees. Through engaging storytelling and case-based discussions with guests ranging from early-career professionals to leading experts, the podcast offers practical strategies that make complex hematology topics accessible and relevant at every career stage. Its mission is to support the educational needs of its audience through high-quality, clinically focused content.